ALLR

Allarity

• Benzinga·03/31 14:24

  Allarity Therapeutics Q4 EPS $(0.21), Inline, Sales $320.000K

• Seeking Alpha·03/31 13:38

  Allarity Therapeutics reports FY results

• Dow Jones·03/31 12:02

  *Allarity Therapeutics 2025 Rev $320,000 >ALLR

• Reuters·03/31 12:00

  ALLARITY THERAPEUTICS REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND CORPORATE PROGRESS

• Dow Jones·03/31 12:00

  *Allarity Therapeutics Sees Year-end 2025 Cash Position of $14.7 M Providing Runway Into Mid-2028 >ALLR

• TipRanks·03/12 16:30

  Allarity’s Terminated Breast Cancer Trial Signals Setback for DRP-Guided Chemotherapy

• NASDAQ·03/09 06:32

  Allarity Secures $20 Million To Propel Stenoparib Toward FDA Approval; Stock Up

• TipRanks·03/06 13:47

  Allarity Therapeutics Secures $20 Million Structured Note Financing

• TipRanks·03/06 13:19

  Allarity closes $20M financing for stenoparib advancement

• Benzinga·03/06 13:11

  Allarity Therapeutics Closes $20M Non-Convertible Debt Funding With Streeterville Capital; Expects Cash Runway To Support Operations Through Mid-2028

• Reuters·03/06 13:01

  Allarity Therapeutics Closes $20 Million Non-Convertible Debt Financing With Streeterville Capital

• Reuters·03/06 13:01

  BRIEF-Allarity Therapeutics Closes $20 Million Financing To Accelerate The Advance Of Stenoparib Toward FDA Approval And Commercialization

• Benzinga·02/20 21:05

  12 Health Care Stocks Moving In Friday's After-Market Session

• TipRanks·02/18 13:25

  Allarity doses first patients in Phase 2 trial of SCLC

• Reuters·02/18 13:15

  Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Relapsed SCLC Trial of Stenoparib Plus Temozolomide